{"Symbol": "CERU", "AssetType": "Common Stock", "Name": "Cerulean Pharma Inc", "Description": "Cerulean Pharma Inc., a clinical-stage company, develops nanopharmaceutical product candidates in the areas of oncology and other diseases in the United States. The company?s lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase II clinical trials for the treatment of relapsed renal cell carcinoma and relapsed ovarian cancer; and in Phase Ib clinical trials for the treatment of neoadjuvant rectal cancer, as well as in Phase II clinical trials for other indications, such as gastric cancer and small cell lung cancer. It is also developing CRLX301, a platform-generated clinical candidate, which is in Phase I clinical development for the treatment of tumor-targeted NDC. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Cambridge, Massachusetts.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Other", "Industry": "Other", "Address": "35 Gatehouse Drive\n02451,Waltham,USA\n", "FullTimeEmployees": "8", "FiscalYearEnd": "December", "LatestQuarter": "None", "MarketCapitalization": "0", "EBITDA": "0", "PERatio": "None", "PEGRatio": "0", "BookValue": "0", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-11.414", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "0", "ReturnOnEquityTTM": "0", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "0", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "3.75", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "0", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "None", "52WeekHigh": "None", "52WeekLow": "None", "50DayMovingAverage": "0", "200DayMovingAverage": "0", "SharesOutstanding": "0", "SharesFloat": "0", "SharesShort": "0", "SharesShortPriorMonth": "0", "ShortRatio": "0", "ShortPercentOutstanding": "0", "ShortPercentFloat": "0", "PercentInsiders": "0", "PercentInstitutions": "0", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}